The National Health Service (NHS) Lothian’s Edinburgh Heart Centre has successfully completed patient recruitment and treatment for the Phase II trial of Elafin for prevention of myocardial injury after coronary artery bypass surgery (CABG). Elafin is a drug candidate of Proteo, Inc. and its subsidiary Proteo Biotech AG. Top-line results are expected to be announced in 1Q14. The study, which began in 3Q11, is a placebo-controlled, double-blinded, Phase II trial to investigate the efficacy and s...